Back to search results

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

IsraelRecruitingPHASE3

Conditions

Generalized Myasthenia Gravis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Honor Health Research Institute, Scottsdale, Arizona, United States

    Contact: Study coordinator (Kristy Osgood) · kosgood@honorhealth.com
    Contact: Principal Investigator (Suraj Muley)

  • Fullerton Neuro and Headache Ctr, Fullerton, California, United States

    Contact: Study coordinator (Alexandra Vasquez) · avasquez@fullertonneuro.net · 714-738-0800
    Contact: Principal Investigator (Jack H Florin)

  • SC3 Research Pasadena, Pasadena, California, United States

    Contact: Study coordinator (Charles Krinel) · Charles.krinel@neurosearch-usa.com
    Contact: Principal Investigator (M Lorraine Purino)

  • California Pacific Medical Center, Sacramento, California, United States

    Study coordinator · 415-600-3604
    Contact: Principal Investigator (Liberty Jenkins)

  • Neurology Offices Of South Florida, Boca Raton, Florida, United States

  • Superior Associates in Research LLC, Hialeah, Florida, United States

  • Augusta University Georgia, Augusta, Georgia, United States

    Contact: Study coordinator (Christian Ryan) · chrryan@augusta.edu · 706-721-6411
    Contact: Principal Investigator (Benjamin Barnes)

  • Hawaii Pacific Neuroscience LLC, Honolulu, Hawaii, United States

  • University of Chicago Medical Centr, Chicago, Illinois, United States

    Contact: Study coordinator (Deekshitha Turaka) · deekshitha.turaka@bsd.uchicago.edu · 773-702-6222
    Contact: Principal Investigator (Kourosh Rezania)

  • Prairie Heart Institute, Springfield, Illinois, United States

    Contact: Study coordinator (Megan Kaler) · mkaler@prairieresearch.com · 217-492-9100
    Contact: Principal Investigator (Raghav Govindarajan)

  • Mid Atlantic Epilepsy and Sleep Ctr, Bethesda, Maryland, United States

    Contact: Principal Investigator (Jonathan Ross)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Principal Investigator (Amanda Guidon)

  • Henry Ford Health System, Detroit, Michigan, United States

    Study coordinator · 313-916-6781
    Contact: Principal Investigator (Kavita Grover)

  • Duke University Medical Center, Durham, North Carolina, United States

    Contact: Study coordinator (Kinjal Patel) · kinjal.patel@emory.edu
    Contact: Principal Investigator (Shruti Raja)

  • Neuroscience Research Ctr, Canton, Ohio, United States

  • Ohio State University Medical Center, Columbus, Ohio, United States

  • Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Thomas Keenan) · thomas.keenan@pennmedicine.upenn.edu · 215-662-8570
    Contact: Principal Investigator (Sami Khella)

  • Vanderbilt University Medical CenterX, Nashville, Tennessee, United States

    Contact: Principal Investigator (Amanda Peltier)

  • Nerve and Muscle Center of Texas, Houston, Texas, United States

    Contact: Study coordinator (Amy Megerle) · houneuamy@msn.com
    Contact: Principal Investigator (Aziz Shaibani.)

  • Central TX Neuro Consultants P A, Round Rock, Texas, United States

  • Center for Neurological Disorders G, Greenfield, Wisconsin, United States

    Contact: Study coordinator (Emily Barraza) · Emily.barraza@cndmilwaukee.com · 414-214-7275
    Contact: Principal Investigator (Bhupendra Khatri)

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, Buenos Aires, Argentina

  • Novartis Investigative Site, Córdoba, Argentina

  • Novartis Investigative Site, Córdoba, Argentina

  • Novartis Investigative Site, Camperdown, Sydney, Australia

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Joinville, Santa Catarina, Brazil

  • Novartis Investigative Site, São Paulo, Brazil

  • Novartis Investigative Site, Hefei, Anhui, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Shenzhen, Guangdong, China

  • Novartis Investigative Site, Shijiazhuang, Hebei, China

  • Novartis Investigative Site, Changsha, Hunan, China

  • Novartis Investigative Site, Suzhou, Jiangsu, China

  • Novartis Investigative Site, Nanchang, Jiangxi, China

  • Novartis Investigative Site, Xi'an, Shaanxi, China

  • Novartis Investigative Site, Xianyang, Shaanxi, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Fujian, China

  • Novartis Investigative Site, Jinan, China

  • Novartis Investigative Site, Copenhagen, Denmark

  • Novartis Investigative Site, Limoges, Haute Vienne, France

  • Novartis Investigative Site, Garches, France

  • Novartis Investigative Site, Nice, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Regensburg, Bavaria, Germany

  • Novartis Investigative Site, Würzburg, Bavaria, Germany

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Bochum, Germany

  • Novartis Investigative Site, Bochum, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Chaïdári, Greece

  • Novartis Investigative Site, Larissa, Greece

  • Novartis Investigative Site, Pátrai, Greece

  • Novartis Investigative Site, Thessaloniki, Greece

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Bologna, BO, Italy

  • Novartis Investigative Site, Florence, FI, Italy

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Palermo, PA, Italy

  • Novartis Investigative Site, Palermo, PA, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Orbassano, TO, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Narita, Chiba, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Nishinomiya, Hyōgo, Japan

  • Novartis Investigative Site, Hanamaki, Iwate, Japan

  • Novartis Investigative Site, Sendai, Miyagi, Japan

  • Novartis Investigative Site, Suita, Osaka, Japan

  • Novartis Investigative Site, Higashi-Matsuyama, Saitama, Japan

  • Novartis Investigative Site, Shinjuku Ku, Tokyo, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukushima, Japan

  • Novartis Investigative Site, Hiroshima, Japan

  • Novartis Investigative Site, Lublin, Lublin Voivodeship, Poland

  • Novartis Investigative Site, Warsaw, Masovian Voivodeship, Poland

  • Novartis Investigative Site, Krakow, POL, Poland

  • Novartis Investigative Site, Katowice, Silesian Voivodeship, Poland

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Krakow, Poland

  • Novartis Investigative Site, Lublin, Poland

  • Novartis Investigative Site, Poznan, Poland

  • Novartis Investigative Site, Rzeszów, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Porto, Portugal

  • Novartis Investigative Site, Vila Nova de Gaia, Portugal

  • Novartis Investigative Site, Belgrade, Serbia

  • Novartis Investigative Site, Niš, Serbia

  • Novartis Investigative Site, Daegu, South Korea

  • Novartis Investigative Site, Gwangju, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Alicante, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Lleida, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Málaga, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Inverness, Invernesshire, United Kingdom

  • Novartis Investigative Site, Ilford, London, United Kingdom

  • Novartis Investigative Site, Swinton, Manchester, United Kingdom

  • Novartis Investigative Site, Birmingham, West Midlands, United Kingdom

  • Novartis Investigative Site, Liverpool, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Southampton, United Kingdom

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)